在癌症中,UHRF1作为表观遗传治疗点
Chun Yang1, Zhitao Yin1, Hexue Yuan1
1Department of Colorectal Surgery, Shenyang Coloproctology Hospital, Shenyang, 110002, Liaoning, China.
Molecular biology reports
|March 3, 2026
概括
在癌症中过度表达的表观遗传调节剂UHRF1,驱动瘤生长和抵抗. 专门针对UHRF1,为下一代癌症治疗提供了一种新的治疗策略,可降低毒性.
科学领域:
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 癌症生物学 癌症生物学
- 分子瘤学分子瘤学
背景情况:
- UHRF1 (与PHD和RING指域1类似于ubiquitin) 是一个关键的表观遗传调节器.
- 过度表达UHRF1与各种癌症有关,促进瘤的进展和治疗耐药性.
- UHRF1集成了DNA甲基化,基因素修饰和无处不在的信号传递.
研究的目的:
- 探索UHRF1作为癌症治疗的可用药物点.
- 调查UHRF1.1的特定领域准策略.
- 审查UHRF1抑制的潜在治疗方法和协同组合.
主要方法:
- 对UHRF1功能和治疗向的现有文献的审查.
- 对针对UHRF1.1的天然化合物和合成抑制剂的分析.
- 探索UHRF1抑制与其他癌症疗法的结合.
主要成果:
- 过度表达UHRF1会使瘤抑制剂沉默,并稳定上蛋白质.
- 域特定的UHRF1抑制提供了一个精致的治疗窗口,毒性降低.
- 包括天然化合物和合成抑制剂在内的各种药物显示出破坏UHRF1.1的潜力.
- 抑制UHRF1可能与DNMT/HDAC抑制剂,免疫疗法和铁致死诱导剂产生协同作用.
结论:
- UHRF1是一个有前途的生物标志物和药物可用标,用于表观遗传癌症疗法.
- 准UHRF1提供了一个精确的策略,与全球表观遗传修饰不同.
- 对UHRF1向疗法的进一步研究具有下一代癌症治疗的巨大潜力.
关键词:
生物标志物生物标志物癌症治疗治疗 癌症治疗通过DNA甲基化.表观遗传调节 表观遗传调节铁性化 (ferroptosis) 是一种免疫调节 免疫调节小分子抑制剂 小分子抑制剂在UHRF1中,UHRF1是更多相关视频
10:44In Vitro Selection of Engineered Transcriptional Repressors for Targeted Epigenetic Silencing
Published on: May 5, 2023
09:56Epigenetic Engineering of K562 Cells: Dual-Vector Episomal Strategy for Stable Targeted DNA Methylation using dCas9-DNMT3A and -HDAC1 Fusion Proteins
Published on: October 31, 2025
相关概念视频
Epigenetic Regulation
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
Epigenetic Regulation
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Epigenetic Regulation
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
